Over 19,000 doses of Sinovac arrive in Bicol | Inquirer News

Over 19,000 doses of Sinovac arrive in Bicol

By: - Correspondent / @msarguellesINQ
/ 06:36 PM June 23, 2021

LEGAZPI CITY — The Department of Health (DOH) here said 19,680 doses of China-made Coronavac vaccines arrived on Wednesday at the Legazpi City Airport.

The vaccines will be allocated to the provinces with Albay getting 3,840 doses, Camarines Norte 1,400 doses, Camarines Sur 9,250 doses, and Sorsogon with 4,920.

The allocated doses for Catanduanes and Masbate will be directly delivered to the island provinces.

Article continues after this advertisement

The vaccines were transported to the DOH Bicol Center for Health Development for inventory.

FEATURED STORIES

The majority of vaccine doses delivered Wednesday are reserved for the second doses of vaccines belonging to the A1, A2, and A3 priority groups.

DOH vaccine statistics said the region has received a total of 258,380 doses. Of this number, 185,921 doses or 72 percent have been administered.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Bicol, COVID-19, Sinovac

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.